VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276
Filed with HKEX · Stock code 2595 · · 3 pages · English
(A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2595) VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276 This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the “Company” or “GenFleet”, together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholder
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Earlier from Genfleet Therapeutics (Shanghai)
- Announcement pursuant to rule 13.10 of the listing rules
- VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase
- 2026 Interim Report
- VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC)
- Voluntary announcement proposed share repurchase on the market
Later from Genfleet Therapeutics (Shanghai)
- Resignation of non-executive director
- List of directors and their roles and functions
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- VOLUNTARY ANNOUNCEMENT GFH375/VS-7375 (Oral KRAS G12D Inhibitor) Achieves Positive Progress across Multiple Clinical Studies in China and Abroad, with Promising Efficacy in Various RAS-mutant Solid Tumors
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)